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Cancer cells are highly variable and largely resistant to therapeutic intervention. Recently,
the use of the tumor necrosis factor related apoptosis-inducing ligand (TRAIL) induced
treatment is gaining momentum due to TRAIL’s ability to specifically target cancers with
limited effect on normal cells. Nevertheless, several malignant cancer types still remain
non-sensitive to TRAIL. Previously, we developed a dynamic computational model, based
on perturbation-response differential equations approach, and predicted protein kinase C
(PKC) as the most effective target, with over 95% capacity to kill human fibrosarcoma
(HT1080) in TRAIL stimulation (1). Here, to validate the model prediction, which has signifi-
cant implications for cancer treatment, we conducted experiments on two TRAIL-resistant
cancer cell lines (HT1080 and HT29). Using PKC inhibitor bisindolylmaleimide I, we demon-
strated that cell viability is significantly impaired with over 95% death of both cancer types,
in consistency with our previous model. Next, we measured caspase-3, Poly (ADP-ribose)
polymerase (PARP), p38, and JNK activations in HT1080, and confirmed cell death occurs
through apoptosis with significant increment in caspase-3 and PARP activations. Finally, to
identify a crucial PKC isoform, from 10 known members, we analyzed each isoform mRNA
expressions in HT1080 cells and shortlisted the highest 4 for further siRNA knock-down
(KD) experiments. From these KDs, PKCδ produced the most cancer cell death in conjunc-
tion with TRAIL. Overall, our approach combining model predictions with experimental
validation holds promise for systems biology based cancer therapy.
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INTRODUCTION
Numerous recent studies have revealed the close link between
inflammation and cancer. First, various types of immune cells,
which support tumor growth progression, are found within the
tumor microenvironment (2,3). Second, the vicinity of cancer cells
displays increased proinflammatory activity, through the detection
of elevated levels of major cytokines such as the tumor necrosis
factor (TNF) (4, 5). One notable cytokine found within the tumor
microenvironment is the TNF related apoptosis-inducing ligand
or TRAIL, which has been shown to induce apoptosis in certain
types of malignant cancers with no significant effect on normal
cells (6, 7). The findings have led to a major stride in the ongoing
research aimed at optimizing TRAIL-induced cancer therapy (8,
9). Despite some success, TRAIL-based therapies still show dis-
mal results for several types of cancers such as the breast cancer,
neuroblastoma, adenocarcinoma, and glioma (10–13).
Computational modeling approaches are becoming increas-
ing useful for interpreting complex dynamical cellular responses
(14–21). Previously, to understand the mechanism for TRAIL-
resistance in cancer,we developed a dynamic computational model
of TRAIL signaling, from extracellular receptor activation to
downstream intracellular activation of cell survival (MAP kinases
and IκB) and apoptosis (caspases-8 and -3) pathways (1). Our
model was based on perturbation-response approach utilizing
first-order response equations (1, 22–29), which was shown to
successfully simulate the temporal experimental profiles IκB, JNK,
p38, caspase-8 and -3 in wildtype, and four (FADD, RIP1, TRAF2,
and caspase-8) knock-down (KD) conditions for human fibrosar-
coma (30). We, subsequently, predicted targeting a novel molecule
interacting with p62 in the model would significantly increase
caspase-3 activation and enhance cancer apoptosis to TRAIL stim-
ulation. Further protein-protein interaction (PPI) database analy-
sis suggested that the novel molecule is most probably a protein
kinase C (PKC) family member.
Here, we tested the model prediction by experimentally ver-
ifying whether targeting PKC will enhance apoptosis in TRAIL-
resistant cancer cell lines. Experiments were performed on TRAIL-
induced human fibrosarcoma (HT1080) and human colon ade-
nocarcinoma (HT29) cells, and the cell viability was compared
with control normal fibroblasts (TIG-1 and MRC-5). Moreover,
to investigate the intracellular mechanisms for resultant cell viabil-
ity, we measured time-course activation levels of caspase-3, PARP,
p38, and JNK. Subsequently, we analyzed the expressions of each
PKC isoform member in HT1080 cells. To identify a crucial tar-
get member for enhanced cancer apoptosis, we prepared relevant
siRNA KD experiments. In summary, our study investigates (i)
whether the model prediction of PKC suppression will enhance
cancer cell death is true, and (ii) whether computational modeling
using perturbation-response approach is valuable for biological
research focusing on cancer treatment.
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MATERIALS AND METHODS
REAGENTS AND CELL CULTURE
Recombinant human TRAIL was purchased from Peprotech.
Bisindolylmaleimide I (BIM-I) was purchased from Merck Mil-
lipore. Human fibrosarcoma cell lines (HT1080), human embryo
fibroblasts (TIG-1), and human colorectal adenocarcinoma cells
(HT29) were obtained from Japanese Collection of Research
Bioresources (JCRB) cell bank. Human fetal lung fibroblasts
(MRC-5) were obtained from American Type Culture Collec-
tion (ATCC). HT1080, TIG-1, HT29, and MRC-5 were grown
in DMEM (Nissui Seiyaku Co.) containing 10% calf serum,
100 U/mL of penicillin, Streptomycin 100µg/ml and Ampho-
tericin B 0.25µg/ml at 37°C in a 5% CO2 humidified atmosphere.
CELL VIABILITY ASSAY
The cell viability was measured by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay and trypan blue
exclusion. MTT assay: cells (10× 104) were inoculated in each
well and incubated for 24 h. Thereafter, 50µL of MTT (2 mg/mL
in PBS) was added to each well and the plates were incubated
for a further 2 h. The resultant formazan was dissolved with
100µL of dimethyl sulfoxide (DMSO) after aspiration of culture
medium. Plates were placed on a plate shaker for 1 min and then
read immediately at 570 nm using TECAN microplate reader with
Magellan software (Männedorf, Switzerland). Trypan blue exclu-
sion: cells were detached with 1 mL of trypsin and suspended in
DMEM. After staining with trypan blue, viable cells were counted
using microscopy (n= 3). The percentage of trypan blue exclusive
viable cells was determined as a percentage of the total number of
cells.
WESTERN BLOT ANALYSIS
Anti-PARP, anti-phospho-p38, and anti-β-actin antibodies were
purchased from Cell Signaling Technology. Proteins were extracted
from the cell lines using radioimmunoprecipitation assay (RIPA)
buffer according to the manufacturer’s instructions. Next, their
concentrations were measured by Bradford protein assay. Equal
amounts of protein were loaded in each well and separated by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE), which was subsequently transferred onto a polyvinylidene
difluoride (PVDF) membrane. The membrane was blocked for
1 h with 5% BSA in TBST on the shaker at room temperature.
The membrane was placed on PARP and p–p38 antibody diluted
at a 1:1000 proportion in diluent buffer [5% (w/v) BSA and 0.1%
Tween 20 in TBS] and incubated overnight at 4°C on the shaker.
The membrane was washed three times in TBS as above and incu-
bated with secondary antibody diluted at a 1:10000 proportion for
1 h on the shaker at room temperature. The membrane was again
washed three times for 5 min each time as above and finally the
results were generated by using an enhanced chemiluminescence
(ECL) Western blotting kit.
ENZYME LINKED IMMUNOSORBENT ASSAYS OF CLEAVED CASPASE-3
AND PHOSPHORYLATED JNK
Cleaved caspase-3 and phosphorylated JNK concentrations were
measured by ELISA Duo Sets IC Kit (R&D Systems) following the
instructions of the manufacturer.
TRANSFECTION
siRNA duplexes were purchased from Sigma. The transfection
of classic PKCs (PKCα, PKCβ, PKCγ), the novel PKCs (PKCδ,
PKCε, PKCη, PKCµ, PKCθ), and the atypical PKCs (PKCζ, PKCι)
and scrambled siRNA were carried out using Lipofectamine 2000
according to the manufacturer’s instructions (Invitrogen).
QUANTITATIVE REAL-TIME PCR ANALYSIS
Total cellular RNA was extracted from cells using the TRIzol
reagent according to the manufacturer’s instructions (Invitrogen).
One microgram of RNA was reverse-transcribed using a first-
strand cDNA synthesis kit (ReverTra Aceα; Toyobo). Quantitative
real-time PCR (qRT-PCR) was performed using SYBR premix Ex
Taq (Takara) on the Applied Biosystems StepOnePlus™ according
to the technical brochure of the company. qRT-PCR primers used
in this study are listed in Table 1. Quantitative measurements were
determined using the ∆∆Ct method and expressions of GAPDH
gene for PKC genes and RPL27 gene for rela, mtor, bcl2, bax, cytoc,
and jun were used as the internal control. Melt curve analyses of
all qRT-PCR products were performed and shown to produce the
sole DNA duplex.
RESULTS
EFFECT OF PKC INHIBITOR IN TRAIL-RESISTANT HT1080 CELLS
Based on our previous computational TRAIL model, the removal
of PKC family members would enhance HT1080 cell death by 95%
(1). Here, we investigated the actual experimental effect of PKC
inhibition to HT1080 cells in TRAIL stimulation. HT1080 cells
were stimulated with 1000 ng/mL of TRAIL in the presence or
absence of 10µM of PKC inhibitor (31–33), BIM-I, pre-treatment
and compared with unstimulated control with and without BIM-
I pre-treatment (Figure 1A). We observed, phenotypically, that
HT1080 cell death was significantly increased in combinatorial
treatment of TRAIL and BIM-I (Figure 1A, forth column), while
control pre-treated with BIM-I did not induce any noticeable cell
death (Figure 1A, second column).
Next, we investigated cell survival ratio using MTT assays for
HT1080 cells pre-treated with BIM-I with increasing dosage (0,
3, and 10µM) for 30 min prior to increasing TRAIL stimulation
(0, 100, 200, 400, and 1000 ng/mL) for 24 h (Figure 1B). Notably,
from these experiments, it is clear that HT1080 cell death is almost
unaffected with any dosage of BIM-I without TRAIL stimulation.
However, when BIM-I was treated in the presence of TRAIL, the
effect synergistically produced significant cell death, compared
with TRAIL alone (Figure 1B). Remarkably, as predicted by our
previous computational TRAIL model (1), the inhibition of PKC
(with 10µM of BIM-I) resulted in about 99% cell death for TRAIL
stimulation (with 100 ng/mL or more) in HT1080 cells. We further
investigated the cell viability of HT1080 with respect to stimula-
tion time, and noticed that significant cell death occurs at 3 h and
onward (Figure 1C).
Next, in addition to HT1080, we also investigated another
TRAIL-resistant cancer cell type (HT29) and compared with nor-
mal fibroblasts (TIG-1 and MRC-5). Experiment-matched MTT
assays revealed that both HT1080 and HT29 cell cultures treated
with BIM-I were sensitized to TRAIL-induced cell death (approx-
imately 99 and 95% cell death, respectively), while normal TIG-1
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Table 1 | List of primer sequences for qRT-PCR.
Name Species Primer name Sequence(5′–3′)
PKCα Human PKCα_F CCACACTAAATCCGCAGTGG
Human PKCα_R CAGCTCCGAAACTCCAAAGGA
PKCβ Human PKCβ_F TTGTGGACCTGAAGGCGAAC
Human PKCβ_R CGGGTGAAAAATCGGTCGAAG
PKCγ Human PKCγ_F GCTTGTAACTACCCCCTGGAAT
Human PKCγ_R GAAGCTGAAGTCGGAGATGTG
PKCδ Human PKCδ_F TGGTGGTTGGTGCGTTGTAG
Human PKCδ_R ATAGGAGTTGAAGGCGATGCG
PKCε Human PKCε_F CAAGCCACCCTTCAAACCAC
Human PKCε_R CGTCCACAAGGGTGAGTACC
PKCη Human PKCη_F GTGTCGTCCATAAACGCTGC
Human PKCη_R ATCCCGAACCTCTGTTCTGC
PKCµ Human PKCµ_F GAGGACGCCAACAGAACCAT
Human PKCµ_R CCTTGCTGGTGTAGTGGACC
PKCθ Human PKCθ_F GCTGATTGGTCAGTCGCCTT
Human PKCθ_R TCTTCTCAGGTTCTCGCACG
PKCζ Human PKCζ_F CACATGCAGAGGCAGAGGAA
Human PKCζ_R GAGGACGTTGTCCAGCTTCA
PKCι Human PKCι_F GCCATCTGCACAGACCGAAT
Human PKCι_R TCCATGGGCATCACTGGTTC
rela Human RelA_F GTGGGGACTACGACCTGAATG
Human RelA_R AGATCTTGAGCTCGGCAGTG
mtor Human mTOR_F TCGCTGAAGTCACACAGACC
Human mTOR_R CTTTGGCATATGCTCGGCAC
bcl2 Human BCL2_F AACATCGCCCTGTGGATGAC
Human BCL2_R TTCACTTGTGGCCCAGATAGG
bax Human BAX_F ACAGGGGCCCTTTTGCTTC
Human BAX_R CTTGGTGGACGCATCCTGAG
cytoc Human Cytochorome c_F AGCGGGAGTGTTCGTTGTG
Human Cytochorome c_R CCTCCCTTTTCAACGGTGTG
jun Human Jun_F ACGGCGGTAAAGACCAGAAG
Human Jun_R CCAAGTTCAACAACCGGTGC
GAPDH Human GAPDH_F GTCAACGGATTTGGTCGTAT
Human GAPDH_R TGGTGATGGGATTTCCATTG
RPL27 Human RPL27_F CTGTCGTCAATAAGGATGTCT
Human RPL27_R CTTGTTCTTGCCTGTCTTGT
and MRC-5 largely survived (Figures 1D,E). These results indicate
that PKC inhibitor, BIM-I, has specific ability to enhance cell death
in TRAIL-resistant cancer cells while having little effect on normal
cells.
TREATMENT OF PKC INHIBITOR WITH TRAIL ENHANCES CELL DEATH
THROUGH APOPTOSIS
The experimental results, so far, are consistent with our previ-
ous model simulations. To further scrutinize the result, that is,
to explore the origins of cell death, we performed analysis to
observe intracellular markers prior to cell death. According to our
model, PKC inhibition causes enhancement of apoptotic path-
ways through signaling flux redistribution (SFR) (1, 22). To check
whether apoptosis is increased in TRAIL stimulated and BIM-I
treated HT1080 cells, we measured PARP cleavage and p38 phos-
phorylation using western blotting assays, and caspase-3 activation
and JNK phosphorylation using enzyme linked immunosorbent
assays (ELISAs) (Figure 2).
Consistent with the prediction of computational model, we
observed substantial induction of PARP and caspase-3 cleav-
age, indicating increased apoptosis in HT1080 cells treated with
BIM-I when compared with untreated cells in TRAIL stimula-
tion (Figure 2A, top panel and Figure 2B, right panel). We further
noticed enhanced p38 activation and low activity of JNK in TRAIL-
stimulated cells treated with BIM-I (Figure 2A, middle panel and
Figure 2B, left panel), in agreement with our model predictions
for SFR at p62 pathway junction (1) (Figure 2C). Note that the
housekeeping protein β-actin remained almost unaffected in the
western blots. These results clearly demonstrate that BIM-I is a
potential therapeutic target for HT1080 treatment.
To examine the expression levels of appropriate genes in
TRAIL-stimulated HT1080, with and without BIM-I, we per-
formed qRT-PCR experiments for several survival and apoptotic
genes (rela, mtor, bcl2, bax, cytoc, and jun) at 0, 20, 40, 60, 120, and
180 min (Figure 3). Except for jun, the levels of genes were stable
for up to 60 min, after which their expressions were significantly
reduced, especially for BIM-I treated HT1080 cells, in correlation
with the cell death dynamics (Figure 1C). These data indicate that,
except for jun, transcription of the genes does not occur, perhaps
due to the increased signaling flux through the apoptosis process
depriving transcriptional signaling and, or due to the repression of
pre- and post-transcriptional mechanisms found during apoptosis
(34–38). Our observations are also consistent with other TRAIL-
induced apoptosis studies investigating gene expressions in HeLa
(35) and MCF7 (36) cells.
Interestingly, jun levels showed an initial decrease during the
first 20 min and then increased and stabilized after 120 min. This
pattern indicates jun may evade the global transcriptional repres-
sion and play a role during apoptosis. Such behavior has been
previously observed for other genes, in particular, genes translated
through internal ribosome entry site (IRES)-mediated translation,
which is known to occur during apoptosis after TRAIL stimula-
tion of MCF7 cells (36, 39). Notably, the presence of IRESs in jun
transcriptional machinery has also been previously shown (40).
Nevertheless, further investigation is required to define the exact
role of jun during TRAIL and BIM-I mediated apoptosis.
Overall, the experiments demonstrate that the enhancement of
cell death of BIM-I pre-treated TRAIL-stimulated cancer occurs
through apoptosis.
IDENTIFICATION OF SPECIFIC PKC ISOFORM TARGET FOR ENHANCED
CELL DEATH
Although we have demonstrated that PKC is a key target to enhance
apoptosis in TRAIL-resistant cancer cells, it is unknown which
PKC family isoform, among the 10 major members (α, β, γ, δ, ε, ι,
θ, η, ζ, and µ), is a crucial single target. To investigate this, we first
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FIGURE 1 |The effect ofTRAIL and PKC inhibitor (BIM-I) on cancer
(HT1080 and HT29) and normal (TIG-1 and MRC-5) cells. (A) Phase
contrast microscopic images of HT1080 cells in the presence or absence
of TRAIL (1000 ng/mL) and/or BIM (10µM). Living cells appear as
adherent cells, while dead cells float in the dish and are highlighted in
white. (B) TRAIL and BIM-I dosage-dependent cell survival (MTT assay)
rates of HT1080 cells (1×105), 24 h after treatment (TRAIL: 0, 100, 200,
400, 1000 ng/mL, BIM-I: 0, 3, 10µM). (C) Cell viability (trypan blue assay)
of HT1080 cells (3×105) at 0 h (no stimulation) and at 1, 3, 12, 24 h after
treatment (TRAIL: 200 ng/mL, BIM-I: 10µM). (D) Cell survival (MTT
assay) rates of HT1080 (1×105), HT29 (1.5×105) cancer cells, and TIG-1
(2×105) normal cells were observed 24 h after treatment in the
presence of TRAIL (200 ng/mL) or BIM-I (10µM), or both, compared to
unstimulated cells (control). (E) BIM-I dosage-dependent (0, 1.25, 2.5, 5,
10, 20µM) cell survival rates of MRC-5 (0.5×105) normal cells after
TRAIL stimulation (200 ng/mL) were obtained through MTT assay after
24 h. Average cell viability is shown in percentage for n=3 independent
experiments. Error bars indicate mean values±SD.
Frontiers in Immunology | Tumor Immunity January 2015 | Volume 5 | Article 659 | 4
Hayashi et al. Systems biology of TRAIL signaling
FIGURE 2 | Enhancement of apoptotic signaling molecules in the
presence of BIM-I inTRAIL-stimulated HT1080 cells. (A) Cleavage of
PARP, phosphorylation of p38, and concentration of β-actin were
determined by western blotting at 0, 30, 60, 120, and 180 min after TRAIL
stimulation (200 ng/mL) of HT1080 cells in absence or presence of BIM-I
(10µM). Right panels represent the quantification of fraction of cleaved
PARP (top, cleaved PARP/total PARP for each time point) and p38
activation (bottom, relative to maximum value of TRAIL stimulation
without BIM-I) using ImageJ (http://imagej.net). (B) Phosphorylation of
JNK and levels of cleaved caspase-3 protein were measured by ELISA at
0, 10, 30, 60, 120, and 180 min after TRAIL stimulation (200 ng/mL) of
HT1080 cells in the absence or presence of BIM-I (10µM). Error bars
indicate mean values±SD for n=3 independent experiments. (C)
Schematic representing the mechanism of signaling flux redistribution at
p62 pathway junction toward p38 and caspase-3 signaling branches
when PKC is inhibited.
measured the mRNA expressions of all 10 isoforms (the sequence
of primers are available in Table 1) in unstimulated HT1080 cells
using qRT-PCR.
We observed the gene expressions of four PKC isoforms (α, δ, ε,
and ι) were noticeably elevated, indicating that these isoforms may
be crucial targets (Figure 4A). To investigate the effect of suppress-
ing each of the four isoforms in TRAIL-stimulated HT1080 cells,
we next performed siRNA-mediated PKC (α, δ, ε, and ι) KDs. The
effect of each PKC KD was first confirmed after 24 h (Figure 4B).
Consequently, we investigated cell viability by trypan blue for each
of the four PKC KD conditions with and without TRAIL stimula-
tion (200 ng/mL). Notably, PKCδ KD produced the most signifi-
cant cell death of approximately 83% after 3 h (Figure 4C). Note
that this result is almost identical to TRAIL-stimulated HT1080
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FIGURE 3 |Temporal relative mRNA expression inTRAIL and
BIM-I treated HT1080 cells. Temporal expression profiles of
anti-apoptotic (rela, mtor, bcl2, and jun) and pro-apoptotic (bax and
cytoc) genes in HT1080 cells at 0, 20, 40, 60, 120, and 180 min after
TRAIL stimulation (200 ng/mL) without (red line) or with (blue line)
pre-treatment of BIM-I (10µM) 30 min prior to TRAIL stimulation.
Note that jun can also be considered as a pro-apoptotic gene (40).
Reported values are the mean expression values (n=3 independent
experiments) relative to time 0 of each condition. Error bars indicate
mean values±SD.
pre-treated with BIM-I at 3 h (Figure 1C). Thus, our experiments
reveal that PKCδ is the optimal single target for enhancing cancer
apoptosis in TRAIL-based therapy.
DISCUSSION
TRAIL, a proinflammatory cytokine produced by the mammalian
immune system, is known to induce apoptosis in cancer cells while
leaving non-diseased cells largely unharmed (41, 42). Hence, there
has been intense interest in using TRAIL has a therapeutic target to
treat cancers (43, 44). However, not all cancers respond to TRAIL
(45, 46).
Previously, we investigated the TRAIL-resistant mechanism in
HT1080 cells using a computational model (1). We predicted
that the suppression of a novel pro-survival molecule would
result in significant enhancement of apoptosis through signal-
ing flux redistribution (22). PPI database search indicated that the
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FIGURE 4 | Identification of the specific PKC isoform target to enhance
apoptosis in HT1080 cells. (A) Relative mRNA expressions of 10 PKC
isoforms in HT1080 unstimulated cells. (B) Effect of siRNA knock-down
(KD) for PKCα, PKCι, PKCε, and PKCδ. HT1080 cells were incubated in the
presence of each PKC isoform siRNA (50µM) for 24 h. Relative mRNA
expressions of four PKC isoforms are measured by qRT-PCR. (C) Cell
viability assay (trypan blue) of HT1080 cells incubated in the presence of
PKC isoforms siRNA (50µM) for 3 h. Error bars indicate mean values±SD.
for n= 3 independent experiments.
pro-survival molecule is a member of PKC. To experimentally val-
idate this result, in this article, we investigated the effects of two
TRAIL-resistant cancer cells to PKC inhibition.
First, using different doses of PKC inhibitor BIM-I together
with various levels of TRAIL stimulation, we observed approxi-
mately 99 and 95% cell death occurred for HT1080 and HT29
cells, respectively (Figure 1). Notably, the effect on control TIG-1
and MRC-5 cells were less significant, at approximately 40 and
20% cell death, respectively.
Second, to confirm the mechanism for cell death is through
apoptosis, we measured the activations of PARP and caspase-3
over 3 h in TRAIL-stimulated HT1080 cells untreated and treated
with BIM-I, and compared with activations of p38 and JNK. We
found that PARP, caspase-3 cleavages and p38 phosphorylation
were significantly enhanced in BIM-I treated cells (Figure 2),
while JNK activity was very low. These results are in consis-
tency with the previous prediction of our computational model
(1). We also investigated the expressions of major pro- and anti-
apoptotic genes, and found them to be mostly repressed at their
transcription levels, especially after 1 h for BIM-I treated cells
(Figure 3).
Third, to identify the crucial PKC family member for single spe-
cific target, we investigated the mRNA expressions of all 10 major
isoforms in HT1080 cells. We selected the top four significantly
expressed isoforms for developing siRNA KDs, and subsequent
experiments demonstrated that PKCδ is a key target for enhancing
cell death in TRAIL-resistant HT1080 cells (Figure 4).
It is worthy to mention other previous works that have stud-
ied PKC in different cancer types (47–50). Although these works
have demonstrated the importance of PKC, the investigations were
performed in different cell lines or stimulations. In this work, how-
ever, we focused mainly on HT1080 and limitedly on HT29 cells.
In addition, we bring to the attention the power of using multidis-
ciplinary research to systemically identify a key target that can be
experimentally tested. Therefore, to our knowledge, this is the first
time the usefulness of a computational model is shown to iden-
tify a consistent and key target for regulating TRAIL-resistance.
In summary, our work provides further evidence for the utility of
systemic approaches in providing effective treatment strategies to
tackle complex diseases.
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